Acknowledgement to Referees.
- Published in:
- Pharmaceutical Medicine, 2024, v. 38, n. 1, p. 1, doi. 10.1007/s40290-023-00511-w
- Publication type:
- Article
Works matching IS 11782595 AND DT 2024 AND VI 38 AND IP 1
Results: 8
1
2
Eliciting Exploratory Patient Preference Data: A Case Study in a Rare Disease.
- Published in:
- Pharmaceutical Medicine, 2024, v. 38, n. 1, p. 55, doi. 10.1007/s40290-023-00509-4
- By:
- Publication type:
- Article
3
Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management.
- Published in:
- Pharmaceutical Medicine, 2024, v. 38, n. 1, p. 25, doi. 10.1007/s40290-023-00508-5
- By:
- Publication type:
- Article
4
"Regulatory Sandboxes" Could Solve the Regulatory Problems Encountered in Europe and Arising from Innovation in Biological Medicinal Products.
- Published in:
- Pharmaceutical Medicine, 2024, v. 38, n. 1, p. 19, doi. 10.1007/s40290-023-00507-6
- By:
- Publication type:
- Article
5
Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials.
- Published in:
- Pharmaceutical Medicine, 2024, v. 38, n. 1, p. 63, doi. 10.1007/s40290-023-00506-7
- By:
- Publication type:
- Article
6
A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications.
- Published in:
- Pharmaceutical Medicine, 2024, v. 38, n. 1, p. 39, doi. 10.1007/s40290-023-00505-8
- By:
- Publication type:
- Article
7
The Importance of Assessing Drug Exposure and Medication Adherence in Evaluating Investigational Medications: Ensuring Validity and Reliability of Clinical Trial Results.
- Published in:
- Pharmaceutical Medicine, 2024, v. 38, n. 1, p. 9, doi. 10.1007/s40290-023-00503-w
- By:
- Publication type:
- Article
8
Medicinal Products and Environmental Pollution.
- Published in:
- Pharmaceutical Medicine, 2024, v. 38, n. 1, p. 5, doi. 10.1007/s40290-023-00502-x
- By:
- Publication type:
- Article